For people living with early-stage Alzheimer’s disease like Mike Zuendel, the clock is ticking after the Centers for Medicare & Medicaid Services (CMS) draft decision that effectively denies access to all current and future FDA-approved treatments targeting amyloid. Mike was diagnosed with mild cognitive impairment due to Alzheimer’s disease at age 66 in 2020, and he has worked to emphasize the benefits of early detection and diagnosis and advocated for addressing the stigma associated with Alzheimer’s disease as a member of the 2021-2022 National Early Stage Advisory Group. He recently shared his story and reaction to the CMS draft decision in the Des Moines Register.
"I, along with millions of other Americans living with early-stage Alzheimer's disease have just days to correct course on a misguided decision proposed by the Centers for Medicare & Medicaid Services, which would severely limit coverage and access to the first Food and Drug Administration-approved treatment to slow the progression of Alzheimer's."
Read Mike's story here.